30-Second Takeaway
- Single‑cell and single‑nucleus eQTL resources are beginning to map neurological GWAS risk to specific brain cell types.
- Secondary variants and modifiers can materially alter phenotype in monogenic syndromes such as PHTS, affecting counseling and surveillance.
- Tiered testing strategies and expanded panels substantially increase diagnostic yield in pediatric hereditary conditions, but unresolved cases remain common.
- Structural variants and repeat expansions require purpose‑built genomic methods for accurate detection, classification, and counseling.
- Functional assays and integrative genomic–transcriptomic workflows are increasingly necessary to resolve non‑coding and splice‑altering VUS in practice.
Week ending March 21, 2026
Genomic tools reshaping risk stratification and variant interpretation across neurogenetics, cancer, and pediatric hereditary disease
Single‑nucleus brain eQTL meta‑analysis links common risk variants to cell‑type‑specific regulatory effects in neurologic disease
This meta‑analysis integrates single‑nucleus RNA‑seq and genotypes from 5.8 million nuclei across 983 European‑ancestry brains. The authors map cis‑ and trans‑eQTLs across major and subtype‑specific brain cell populations, including disease‑specific and sex‑specific effects. They report up to a tenfold increase in cis‑eQTL discovery compared with previous approaches, revealing highly cell‑type‑specific regulatory architectures. Colocalization and Mendelian randomization highlight genes whose expression mediates neurological disease risk, informing variant interpretation in neurogenetics. The resulting SingleBrain resource provides a reference for assigning GWAS variants to target genes and relevant brain cell types.
Cerebellar single‑cell eQTLs implicate oligodendrocyte BACE2 dysregulation and demyelination in essential tremor
Investigators constructed a single‑cell atlas of more than 1 million cerebellar cortical cells from 109 individuals. Single‑cell eQTL and Mendelian randomization analyses link essential tremor risk variants at the BACE2 locus to its downregulation in cerebellar oligodendrocytes. They identify a genetically vulnerable population of BACE2‑expressing immature oligodendrocytes, suggesting a demyelinating contribution to essential tremor pathogenesis. The study also infers disrupted interactions between neuronal populations and oligodendrocytes, emphasizing non‑neuronal mechanisms in this common movement disorder.
Secondary variants and modifier loci help explain cancer versus neurodevelopmental divergence in PTEN hamartoma tumor syndrome
Whole‑genome sequencing of 599 individuals with PTEN hamartoma tumor syndrome and relatives yielded 543 probands for analysis. Among probands, 6.8% carried pathogenic or likely pathogenic variants in other cancer‑associated genes, notably MITF, DICER1, and BRCA2. An additional 7.9% harbored variants in neurodevelopmental‑disorder genes such as DHCR7, POLG, and ARSA, partially explaining phenotype clustering. Genome‑wide analyses detected candidate modifier loci functionally connected to PTEN, including ZNF713, TPTE2P1, and PDPK1. These data support complex gene–gene interactions shaping malignant versus neurodevelopmental outcomes, informing individualized risk stratification and counseling in PHTS.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.